Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Beneish M-Score: -2.22 (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06990 Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
44 GF Score
Price HK$523.00
GF Value HK$254.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sichuan Kelun-Biotech Biopharmaceutical Co Beneish M-Score?

Sichuan Kelun-Biotech Biopharmaceutical Co HKSE:06990 -2.79% 44 Beneish M-Score is -2.22 as of Aug. 24, 2026. GuruFocus rates HKSE:06990 with a GF Score™ of 44/100 and a GF Value™ of HK$254.91 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 829 Biotechnology companies, Sichuan Kelun-Biotech Biopharmaceutical Co ranks worse than 55.85% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.22 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score or its related term are showing as below:

HKSE:06990' s Beneish M-Score Range Over the Past 10 Years
Min: -3.24   Med: -2.22   Max: -0.15
Current: -2.22

During the past 5 years, the highest Beneish M-Score of Sichuan Kelun-Biotech Biopharmaceutical Co was -0.15. The lowest was -3.24. And the median was -2.22.

Sichuan Kelun-Biotech Biopharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Kelun-Biotech Biopharmaceutical Co Beneish M-Score Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
0.00 0.00 -3.24 -0.15 -2.22

Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.15 0.00 -2.22 0.00

HKSE:06990 vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score falls into.


HKSE:06990
44GF Score
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd HKSE:06990
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Kelun-Biotech Biopharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sichuan Kelun-Biotech Biopharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3104+0.528 * 0.9169+0.404 * 1.5507+0.892 * 1.1015+0.115 * 0.9218
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.0694+4.679 * -0.033676-0.327 * 0.8352
=-2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$112 Mil.
Revenue was HK$2,273 Mil.
Gross Profit was HK$1,634 Mil.
Total Current Assets was HK$5,688 Mil.
Total Assets was HK$6,616 Mil.
Property, Plant and Equipment(Net PPE) was HK$798 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$111 Mil.
Selling, General, & Admin. Expense(SGA) was HK$315 Mil.
Total Current Liabilities was HK$1,110 Mil.
Long-Term Debt & Capital Lease Obligation was HK$49 Mil.
Net Income was HK$-422 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$-199 Mil.
 Total Receivables was HK$78 Mil.
Revenue was HK$2,064 Mil.
Gross Profit was HK$1,360 Mil.
Total Current Assets was HK$3,729 Mil.
Total Assets was HK$4,557 Mil.
Property, Plant and Equipment(Net PPE) was HK$770 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$98 Mil.
Selling, General, & Admin. Expense(SGA) was HK$138 Mil.
Total Current Liabilities was HK$865 Mil.
Long-Term Debt & Capital Lease Obligation was HK$91 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(112.27 / 2273.436) / (77.776 / 2063.858)
=0.049383 / 0.037685
=1.3104

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1359.848 / 2063.858) / (1633.647 / 2273.436)
=0.658886 / 0.718581
=0.9169

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5687.826 + 798.168) / 6615.696) / (1 - (3729.171 + 770.046) / 4556.827)
=0.019605 / 0.012643
=1.5507

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2273.436 / 2063.858
=1.1015

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(97.57 / (97.57 + 770.046)) / (110.91 / (110.91 + 798.168))
=0.112458 / 0.122003
=0.9218

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(314.533 / 2273.436) / (137.978 / 2063.858)
=0.138351 / 0.066854
=2.0694

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((48.655 + 1109.69) / 6615.696) / ((90.651 + 864.645) / 4556.827)
=0.17509 / 0.209641
=0.8352

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-421.973 - 0 - -199.182) / 6615.696
=-0.033676

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sichuan Kelun-Biotech Biopharmaceutical Co has a M-score of -2.22 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.22 mean?
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a Beneish M-Score of -2.22 as of Aug. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #463 out of 829 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current Beneish M-Score is -2.22. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #463 out of 829 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #463 out of 829 companies for Beneish M-Score. This places Sichuan Kelun-Biotech Biopharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. Sichuan Kelun-Biotech Biopharmaceutical Co's current Beneish M-Score is -2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current Beneish M-Score is -2.22. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current Beneish M-Score is -2.22 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued. The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91. GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.

Key valuation signals for HKSE:06990:

  • Beneish M-Score: -2.22
  • GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sichuan Kelun-Biotech Biopharmaceutical Co Business Description

Address No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score

Get the complete analysis for HKSE:06990

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$523.00
Price
HK$254.91
GF Value